Precision Radiation Oncology · Published 2025-12-01 · DOI 10.1002/pro6.70043
Abstract Background and purpose Current evidence is insufficient to define the value of thoracic radiotherapy (TRT) following chemoimmunotherapy (CT‐IO) in extensive‐stage small‐cell lung cancer (ES‐SCLC). We aimed to ascertain whether incorporating immunotherapy (IO) could improve survival and explore the efficacy of TRT in combination with CT‐IO among patients with ES‐SCLC. Methods Clinical data were retrospectively analyzed. Patients were classified into two groups: IO and chemoradiotherapy (CRT). Within the IO group, we further defined two subgroups: CT‐IO and chemoradioimmunotherapy (CRT‐IO) groups. Results A total of 206 patients were enrolled in this study. The median overall survival was 22.2 months in the CRT‐IO group, which was longer than the 16.0 months observed in the CT‐IO group (P = 0.002) and 19.0 months noted in the CRT group (P = 0.208). The objective response rate (ORR) in the CRT‐IO group (69.8%) was better than that in the CT‐IO (68.9 %, P = 0.929) and CRT (59.3 %, P = 0.227) groups. Conclusions Considering the trend toward prolonged survival and a higher ORR in the CRT‐IO group, TRT may be feasible in IO era. Considering the economic factors and physical conditions, CRT may be an option for patients with ES‐SCLC.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →